Home LiteratureArticle Details
PMID: 16465192 Published · ppublish English Journal Article Review

Targeted therapy for metastatic renal cell carcinoma.

British journal of cancer ·Vol. 94 ·No. 5 ·2006-03-13 ·Pages 614-9

Patel PH, Chaganti RS, Motzer RJ

Abstract

Metastatic renal cell carcinoma (RCC) has historically been refractory to cytotoxic and hormonal agents; only interleukin 2 and interferon alpha provide response in a minority of patients. We reviewed RCC biology and explored the ways in which this understanding led to development of novel, effective targeted therapies. Small molecule tyrosine kinase inhibitors, monoclonal antibodies and novel agents are all being studied, and phase II studies show promising activity of sunitinib, sorafenib and bevacizumab. The results of phase III studies will determine the role of these agents in metastatic RCC.

MeSH Terms
Antibodies, Monoclonal/therapeutic use Antibodies, Monoclonal, Humanized Benzenesulfonates/therapeutic use Bevacizumab Carcinoma, Renal Cell/drug therapy,secondary Clinical Trials as Topic Enzyme Inhibitors/therapeutic use Humans Indoles/therapeutic use Kidney Neoplasms/drug therapy,pathology Neoplasm Metastasis Niacinamide/analogs & derivatives Phenylurea Compounds Protein-Tyrosine Kinases/antagonists & inhibitors Pyridines/therapeutic use Pyrroles/therapeutic use Sorafenib Sunitinib
Chemicals
Antibodies, Monoclonal Antibodies, Monoclonal, Humanized Benzenesulfonates Enzyme Inhibitors Indoles Phenylurea Compounds Pyridines Pyrroles Niacinamide Bevacizumab Sorafenib Protein-Tyrosine Kinases Sunitinib
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Patel P H
Department of Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA.
Chaganti R S K
Motzer R J
References (31)
31 references, click to expand
  1. Searching for the hereditary causes of renal-cell carcinoma.
    Nat Rev Cancer. 2004 May;4(5):381-93 PMID: 15122209
  2. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.
    Clin Cancer Res. 2003 Jan;9(1):327-37 PMID: 12538485
  3. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
    Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6282S-9S PMID: 15448018
  4. Prognostic factors for survival of patients with stage IV renal cell carcinoma: memorial sloan-kettering cancer center experience.
    Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6302S-3S PMID: 15448021
  5. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis.
    Cancer Res. 2004 Oct 1;64(19):7099-109 PMID: 15466206
  6. Mutation and cancer: statistical study of retinoblastoma.
    Proc Natl Acad Sci U S A. 1971 Apr;68(4):820-3 PMID: 5279523
  7. A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.
    N Engl J Med. 1987 Apr 9;316(15):889-97 PMID: 3493432
  8. Mutator phenotype may be required for multistage carcinogenesis.
    Cancer Res. 1991 Jun 15;51(12):3075-9 PMID: 2039987
  9. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis.
    Nature. 1992 Oct 29;359(6398):843-5 PMID: 1279431
  10. General involvement of hypoxia-inducible factor 1 in transcriptional response to hypoxia.
    Proc Natl Acad Sci U S A. 1993 May 1;90(9):4304-8 PMID: 8387214
  11. Silencing of the VHL tumor-suppressor gene by DNA methylation in renal carcinoma.
    Proc Natl Acad Sci U S A. 1994 Oct 11;91(21):9700-4 PMID: 7937876
  12. Renal-cell carcinoma.
    N Engl J Med. 1996 Sep 19;335(12):865-75 PMID: 8778606
  13. Rbx1, a component of the VHL tumor suppressor complex and SCF ubiquitin ligase.
    Science. 1999 Apr 23;284(5414):657-61 PMID: 10213691
  14. Rising incidence of renal cell cancer in the United States.
    JAMA. 1999 May 5;281(17):1628-31 PMID: 10235157
  15. Targeting the mitogen-activated protein kinase cascade to treat cancer.
    Nat Rev Cancer. 2004 Dec;4(12):937-47 PMID: 15573115
  16. Role of VHL gene mutation in human cancer.
    J Clin Oncol. 2004 Dec 15;22(24):4991-5004 PMID: 15611513
  17. Phase I clinical and pharmacokinetic study of the Novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.
    J Clin Oncol. 2005 Feb 10;23(5):965-72 PMID: 15613696
  18. A small molecule-kinase interaction map for clinical kinase inhibitors.
    Nat Biotechnol. 2005 Mar;23(3):329-36 PMID: 15711537
  19. Mammalian target of rapamycin.
    Semin Oncol. 2004 Dec;31(6 Suppl 16):10-7; discussion 33 PMID: 15799239
  20. Erlotinib in lung cancer - molecular and clinical predictors of outcome.
    N Engl J Med. 2005 Jul 14;353(2):133-44 PMID: 16014883
  21. Tyrosine kinases as targets for cancer therapy.
    N Engl J Med. 2005 Jul 14;353(2):172-87 PMID: 16014887
  22. Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.
    J Clin Oncol. 2005 Nov 1;23(31):7889-96 PMID: 16204015
  23. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
    J Clin Oncol. 2006 Jan 1;24(1):16-24 PMID: 16330672
  24. Patterns of aneuploidy in stage IV clear cell renal cell carcinoma revealed by comparative genomic hybridization and spectral karyotyping.
    Genes Chromosomes Cancer. 2003 Jul;37(3):252-60 PMID: 12759923
  25. Activation of HIF1alpha ubiquitination by a reconstituted von Hippel-Lindau (VHL) tumor suppressor complex.
    Proc Natl Acad Sci U S A. 2000 Sep 12;97(19):10430-5 PMID: 10973499
  26. Structural basis for the recognition of hydroxyproline in HIF-1 alpha by pVHL.
    Nature. 2002 Jun 27;417(6892):975-8 PMID: 12050673
  27. Rules for making human tumor cells.
    N Engl J Med. 2002 Nov 14;347(20):1593-603 PMID: 12432047
  28. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer.
    N Engl J Med. 2003 Jul 31;349(5):427-34 PMID: 12890841
  29. Hypoxia-inducible factor-1 and oncogenic signalling.
    Bioessays. 2004 Mar;26(3):262-9 PMID: 14988927
  30. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma.
    J Clin Oncol. 2004 Mar 1;22(5):909-18 PMID: 14990647
  31. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
    Proc Natl Acad Sci U S A. 2004 Sep 7;101(36):13306-11 PMID: 15329413
Article Info
Journal
British journal of cancer
Abbr.
Br J Cancer
ISSN
0007-0920
DOI
10.1038/sj.bjc.6602978
Published
2006-03-13
Pages
614-9
Language
English
Region
England
NLM ID
0370635
PMCID
PMC2361211
Subset
IM
External Links
PubMed source DOI: 10.1038/sj.bjc.6602978 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2